LSA
BMRN icon

Leonteq Securities AG’s BioMarin Pharmaceuticals BMRN Stock Holding History

Leonteq Securities AG’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$206K Buy
3,598
+127
+4% +$6.96K 0.01% 564
2026
Q1 		$196K Sell
3,471
-2,242
-39% -$131K 0.01% 604
2025
Q4 		$340K Sell
5,713
-20,837
-78% -$1.13M 0.01% 547
2025
Q3 		$1.44M Buy
26,550
+21,784
+457% +$1.25M 0.04% 240
2025
Q2 		$262K Sell
4,766
-320
-6% -$18.8K 0.01% 511
2025
Q1 		$360K Sell
5,086
-6,919
-58% -$465K 0.02% 423
2024
Q4 		$789K Buy
12,005
+3,216
+37% +$215K 0.05% 280
2024
Q3 		$618K Buy
8,789
+5,435
+162% +$454K 0.05% 287
2024
Q2 		$276K Buy
3,354
+1,882
+128% +$157K 0.02% 419
2024
Q1 		$129K Buy
1,472
+1,161
+373% +$104K 0.01% 593
2023
Q4 		$30K Sell
311
-1,270
-80% -$112K ﹤0.01% 874
2023
Q3 		$140K Sell
1,581
-4,248
-73% -$378K 0.01% 593
2023
Q2 		$505K Buy
5,829
+2,548
+78% +$240K 0.03% 387
2023
Q1 		$319K Sell
3,281
-1,606
-33% -$166K 0.01% 447
2022
Q4 		$506K Sell
4,887
-2,443
-33% -$229K 0.02% 381
2022
Q3 		$621K Sell
7,330
-3,386
-32% -$301K 0.02% 339
2022
Q2 		$888K Sell
10,716
-13,281
-55% -$1.06M 0.03% 303
2022
Q1 		$1.85M Buy
23,997
+7,979
+50% +$668K 0.07% 212
2021
Q4 		$1.42M Sell
16,018
-29,079
-64% -$2.4M 0.05% 271
2021
Q3 		$3.49M Sell
45,097
-1,325
-3% -$105K 0.15% 123
2021
Q2 		$3.87M Sell
46,422
-23,334
-33% -$1.85M 0.23% 89
2021
Q1 		$5.27M Buy
69,756
+42,758
+158% +$3.49M 0.31% 70
2020
Q4 		$2.37M Buy
+26,998
New +$2.14M 0.13% 142

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Leonteq Securities AG's BMRN Position: Q2 2026 in Review

Leonteq Securities AG increased its BioMarin Pharmaceuticals (BMRN) stake by 3.7% in Q2 2026, buying an estimated $6.96K and bringing the position to 3,598 shares worth $206K. The position accounts for 0.01% of the portfolio, ranked #564.

Leonteq Securities AG first reported a position in BMRN in Q4 2020 and has held it in 23 quarters since. The position peaked at $5.27M in Q1 2021. 561 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Leonteq Securities AG held 3,598 shares of BioMarin Pharmaceuticals worth $206K as of Q2 2026.
  • Leonteq Securities AG bought 127 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $6.96K.
  • BioMarin Pharmaceuticals made up 0.01% of Leonteq Securities AG's portfolio in Q2 2026, its #564 holding.
  • Leonteq Securities AG first reported a position in BioMarin Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Leonteq Securities AG's BioMarin Pharmaceuticals position peaked at $5.27M in Q1 2021.
  • 561 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Leonteq Securities AG's 13F filing for Q2 2026, filed 27 Jul 2026.